| pubmed-article:9663596 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0036864 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0337810 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0242781 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C1521797 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C0033105 | lld:lifeskim |
| pubmed-article:9663596 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:9663596 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9663596 | pubmed:dateCreated | 1998-7-28 | lld:pubmed |
| pubmed-article:9663596 | pubmed:abstractText | Three hundred seventy-nine individuals [137 non-injecting drug using (non-IDU) heterosexuals, 130 homosexual men and 112 IDU] attending the human immunodeficiency virus (HIV) testing program of a sexually transmitted disease (STD) clinic in Rome were studied to estimate the prevalence and to identify the modalities of transmission of human herpesvirus-8 (HHV-8) infection. Serological analysis was performed by using an immunofluorescence assay able to detect anti-latent and anti-lytic HHV-8 antibodies. Twelve acquired immunodeficiency syndrome (AIDS)-Kaposi's sarcoma (KS) patients and 94 blood donors were tested as reference population groups. Anti-lytic antibodies were detected in 185 (48.8%) individuals; 52 of them (13.7%) also had anti-latent antibodies. Both anti-lytic and anti-latent antibody prevalence were higher among homosexual men (66.9% and 27.7%, respectively) than among IDU (49.1% and 8.0%, respectively) and non-IDU heterosexuals (31.4% and 5.1%, respectively), and tended to increase with age. Anti-lytic HHV-8 antibodies were associated with syphilis [odds ratio (OR)=3.81] but not with hepatitis C virus (HCV) seropositivity. HIV-infected homosexual men were more likely to have HHV-8 antibodies than those who were HIV-negative. When using anti-latent antibodies the direction of the OR remained the same, although the associations did not often reach statistical significance. Among AIDS-KS patients, 83.3% had anti-lytic and 66.6% had anti-latent antibodies. Among blood donors, 28% had anti-lytic antibodies and 2 of them (2.1%) also had anti-latent antibodies. Our data indicate that HHV-8 seroprevalence increases with age and is higher among homosexual men, particularly those infected with HIV. This is consistent with sexual transmission of HHV-8 infection. In addition, the presence of HHV-8 antibodies in HIV-negative non-IDU heterosexual contacts and in healthy blood donors is consistent with the high incidence of classic KS in Italy. | lld:pubmed |
| pubmed-article:9663596 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9663596 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9663596 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9663596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9663596 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9663596 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9663596 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:LevyJ AJA | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:LennetteE TET | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:Di CarloAA | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:CaprilliFF | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:GiulianiMM | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:LodiGG | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:EnsoliBB | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:RezzaGG | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:MoniniPP | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:PezzottiPP | lld:pubmed |
| pubmed-article:9663596 | pubmed:author | pubmed-author:ButtòSS | lld:pubmed |
| pubmed-article:9663596 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9663596 | pubmed:day | 29 | lld:pubmed |
| pubmed-article:9663596 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:9663596 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9663596 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9663596 | pubmed:pagination | 361-5 | lld:pubmed |
| pubmed-article:9663596 | pubmed:dateRevised | 2007-7-24 | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:meshHeading | pubmed-meshheading:9663596-... | lld:pubmed |
| pubmed-article:9663596 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9663596 | pubmed:articleTitle | Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. | lld:pubmed |
| pubmed-article:9663596 | pubmed:affiliation | Centro Operativo AIDS-Laboratory of Epidemiology and Biostatistics, Istituto Superiore di Sanità, Rome, Italy. g.rezza@net.iss.it | lld:pubmed |
| pubmed-article:9663596 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9663596 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9663596 | lld:pubmed |
